{"abuse":["Abuse"],"adverse_reactions":["ADVERSE REACTIONS Hypersensitivity reactions such as rash, urticaria, leukopenia, agranulocytosis, and thrombocytopenia may occur. Other adverse reactions to these tablets may be drowsiness, lassitude, giddiness, dryness of the mucous membranes, tightness of the chest, thickening of bronchial secretions, urinary frequency and dysuria, palpitation, tachycardia, hypotension/hypertension, faintness, dizziness, tinnitus, headache, in coordination, visual disturbances, mydriasis, xerostomia, blurred vision, anorexia, nausea, vomiting, diarrhea, constipation, epigastric distress, hyperirritability, nervousness and insomnia. Large overdoses may cause tachypnea, delirium, fever, stupor, coma, and respiratory failure. Hyper-reactive individuals may display ephedrine-like reactions such as tachycardia, palpitations, headache, dizziness, or nausea. Sympathomimetics have been associated with certain untoward reactions including fear, anxiety, nervousness, dysuria, insomnia, hallucinations, convulsions, CNS depression, arrhythmias, and cardiovascular collapse with hypotension. Very rarely dermatitis may occur in response to antihistamines. Patient idiosyncrasy to adrenergic agents may be manifested by insomnia, dizziness, weakness, tremor or arrhythmias."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No data are available on the long-term potential of the components of this product for carcinogenesis, mutagenesis, or impairment of fertility in animals or humans."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Pseudoephedrine hydrochloride exerts a vasoconstrictive and decongestive action while chlorpheniramine maleate decreases the symptoms of watering eyes, post-nasal drip, and sneezing which may be associated with an allergic like response. The belladonna alkaloids, hyoscyamine, atropine, and scopolamine further augment the anti-secretory activity of these tablets. Pseudoepherdine is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. It does this by vasoconstriction which results in reduction of tissue hyperemia, edema, nasal congestion, and an increase in nasal airway patency. The vasoconstriction action of pseudoephedrine is similar to that of ephedrine. In the usual dose it has minimal vasopressor effects. Pseudoephedrine is rapidly and almost completely absorbed from the gastrointestinal tract. It has a plasma half-life of 6-8 hours. Alkaline urine is associated with slower elimination of the drug. The drug distributed to body tissues and fluids, including the central nervous system (CNS). Approximately 50%-75% of the administered dose is excreted unchanged in the urine; the remainder is apparently metabolized in the liver to inactive compounds by N-demethylation, parahydroxylation and oxidative deamination. Chlorpheniramine is an antihistaminic that possesses anticholinergic and sedative effects. It is considered one of the most effective and least toxic of the histamine antagonists. Chlorpheniramine is an H 1 receptor antagonist. It antagonizes many of the pharmacological actions of histamine. It prevents released histamine from dilating capillaries and causing edema of the respiratory mucosa. Chlorpheniramine has a duration of action of 4-6 hours. Its half-life in serum is 12-16 hours. Degradation products of chlorpheniramine's metabolic transformation by the liver are almost completely excreted in 24 hours."],"contraindications":["CONTRAINDICATIONS Contraindicated in patients with hypersensitivity to sympathomimetics'9ll1lhistamines, belladonna alkaloids or to any of the ingredients\" in' this product. These tablets are contraindicated in children under 12 years of age and in patients with glaucoma, urinary retention, peptic ulcer, bronchial asthma, and women who are pregnant or -nursing. Also contraindicated in patients with serve hypertension, severe coronary artery disease and patients currently on monoamine oxidase inhibitor (MAOI) therapy and for 14 days after stopping MAOI therapy (See Drug Interactions section)."],"controlled_substance":["Controlled Substance"],"dependence":["Dependence"],"description":["DESCRIPTION Each prolonged action, dye-free, sugar-free tablet contains: Pseudoephedrine Hydrochloride ................................ 90 mg Chlorphenramine (Hyoscyamine) ............................. 8 mg Belladonna Alkaloids (Hyoscyamine Sulfate, Atropine Sulfate and Scopolamine Hydrobromide) ..................................... 0.24 mg Pseudoephedrine hydrochloride is a nasal decongestant having the chemical name benzenemethanol, α-[1-methylamino)ethyl]-,[S-(R*, R*)]-, hydrochloride. Chlorpheniramine maleate is an antihistamine having the chemical name 2-pyridinepropanamine, y -(4-chlorophenyl)-N, N-dimethyl-, (Z) 2-butenedioate (1 :1). Chemically, atropine sulfate is an anti-secretory having the chemical name benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, endo-(±)-, sulfate (2:1) (salt), monohydrate. Chemically, hyoscyamine sulfate is an anti-secretory having the chemical name benzeneacetic acid, α-(hydroxymethyl)-, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, [3(S)-endo ] -, sulfate (2:1), dihydrate. Chemically, scopolamine hydrobromide is an anti-secretory having the chemical name benzeneacetic acid, α-(hydroxymethyl)-, 9-methyl-3oxa-9-azatricyclo[3.3.1.0 2.4 ]non-7-yl ester, hydrobromide, trihydrate, [7(S)-(1α ,2 ß,4ß, 5α, 7 ß, )]"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Usual Dosage: Adults and children over 12 years of age 1 tablet morning and evening not to exceed two tablets in 24 hours. This product is not recommended for children under 12 years of age."],"drug_abuse_and_dependence":["DRUG ABUSE AND DEPENDENCE Controlled Substance Abuse Dependence"],"drug_and_or_laboratory_test_interactions":["Drug/Laboratory Test Interactions Antihistamines may suppress the wheal and flare reactions to antigen skin testing."],"drug_interactions":["Interactions Drug Interactions Do not prescribe this product for use in patients taking a prescription MAOI (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 14 days after stopping the MAOI drug therapy. Beta-adrenegeric blockers and MAO inhibitors may potentiate the pressor effect of pseudoephedrine HCI. Concurrent use of digitalis glycosides may increase the possibility of cardiac arrhythmias. Sympathomimetics may reduce the hypotensive effects of guanethidine, mecamylamine, methyldopa, reserpine, and veratrum alkaloids. Concurrent use of tricyclic antidepressants may antagonize the effects of pseudoephendrine. Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates and other CNS depressants may have an additive effect. Drug/Laboratory Test Interactions Antihistamines may suppress the wheal and flare reactions to antigen skin testing.","Drug Interactions Do not prescribe this product for use in patients taking a prescription MAOI (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 14 days after stopping the MAOI drug therapy. Beta-adrenegeric blockers and MAO inhibitors may potentiate the pressor effect of pseudoephedrine HCI. Concurrent use of digitalis glycosides may increase the possibility of cardiac arrhythmias. Sympathomimetics may reduce the hypotensive effects of guanethidine, mecamylamine, methyldopa, reserpine, and veratrum alkaloids. Concurrent use of tricyclic antidepressants may antagonize the effects of pseudoephendrine. Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates and other CNS depressants may have an additive effect."],"effective_time":"20110322","general_precautions":["General Use with caution in patients with diabetes, hypertension, cardiovascular disease, cardiac or peripheral vascular disease, hyperthyroidism and intolerance to ephedrine. These tablets contain belladonna alkaloids and must be administered with care to those patients with urinary bladder neck obstruction. May cause drowsiness and/or impair mental alertness"],"geriatric_use":["Geriatric Use Patients 60 years and older are more likely to experience adverse reactions to sympathomimetics. Overdose of sympathomimetics in this age group may cause hallucinations, convulsions, CNS depression, and death."],"how_supplied":["HOW SUPPLIED Bottles of 100 (NDC 60575-177-19). White scored tablets debossed with \"RESPA 177\" on one side and blank on the scored side. Store at controlled room temperature between 20°-25°C (68°-77°F)."],"id":"b5a4d051-7a41-45b3-b518-1c833044abb7","indications_and_usage":["INDICATIONS AND USAGE These tablets are indicated for the relief of symptoms resulting from irritation of sinus, nasal and upper respiratory tract tissues."],"information_for_patients":["Information for Patients Do not crush or chew this product prior to swallowing. Patients should be instructed to check with physician if symptoms do not improve within 5 days or if fever is present. May cause drowsiness and/or impair mental alertness. Patients should be warned not to operate motor vehicles, heavy machinery or engage in hazardous tasks, and that product should not be used with alcohol, certain antidepressants, barbiturates or other CNS depressants."],"labor_and_delivery":["Labor and Delivery"],"laboratory_tests":["Laboratory Tests"],"nonteratogenic_effects":["Nonteratogenic Effects"],"nursing_mothers":["Nursing Mothers This product contains pseudoephedrine which is excreted in breast milk. Use of this product by nursing mothers is not recommended because of the higher than usual risk to infants from sympathomimetic amines."],"openfda":{},"overdosage":["OVERDOSAGE Since the action of sustained release products may continue for as long as 12 hours, treatment of overdoses directed at reversing the effects of the drug and supporting the patient should be maintained for at least that length of time. Saline cathartics are useful for hastening evacuation of unreleased medication. In children and infants, antihistamine overdosage may produce convulsions and death."],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL CONTAINER LABEL 6486 CL"],"pediatric_use":["Pediatric Use This product is not recommended for use in children under 12 years of age."],"precautions":["PRECAUTIONS General Use with caution in patients with diabetes, hypertension, cardiovascular disease, cardiac or peripheral vascular disease, hyperthyroidism and intolerance to ephedrine. These tablets contain belladonna alkaloids and must be administered with care to those patients with urinary bladder neck obstruction. May cause drowsiness and/or impair mental alertness Information for Patients Do not crush or chew this product prior to swallowing. Patients should be instructed to check with physician if symptoms do not improve within 5 days or if fever is present. May cause drowsiness and/or impair mental alertness. Patients should be warned not to operate motor vehicles, heavy machinery or engage in hazardous tasks, and that product should not be used with alcohol, certain antidepressants, barbiturates or other CNS depressants. Laboratory Tests Interactions Drug Interactions Do not prescribe this product for use in patients taking a prescription MAOI (certain drugs for depression, psychiatric or emotional conditions, or Parkinson's disease), or for 14 days after stopping the MAOI drug therapy. Beta-adrenegeric blockers and MAO inhibitors may potentiate the pressor effect of pseudoephedrine HCI. Concurrent use of digitalis glycosides may increase the possibility of cardiac arrhythmias. Sympathomimetics may reduce the hypotensive effects of guanethidine, mecamylamine, methyldopa, reserpine, and veratrum alkaloids. Concurrent use of tricyclic antidepressants may antagonize the effects of pseudoephendrine. Concomitant use of antihistamines with alcohol, tricyclic antidepressants, barbiturates and other CNS depressants may have an additive effect. Drug/Laboratory Test Interactions Antihistamines may suppress the wheal and flare reactions to antigen skin testing. Carcinogenesis, Mutagenesis, Impairment of Fertility No data are available on the long-term potential of the components of this product for carcinogenesis, mutagenesis, or impairment of fertility in animals or humans. Pregnancy Category C: Animal reproduction studies have not been conducted with this product. It is not known whether these drugs can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. This product is not recommended for use during pregnancy. Teratogenic Effects Nonteratogenic Effects Labor and Delivery Nursing Mothers This product contains pseudoephedrine which is excreted in breast milk. Use of this product by nursing mothers is not recommended because of the higher than usual risk to infants from sympathomimetic amines. Pediatric Use This product is not recommended for use in children under 12 years of age. Geriatric Use Patients 60 years and older are more likely to experience adverse reactions to sympathomimetics. Overdose of sympathomimetics in this age group may cause hallucinations, convulsions, CNS depression, and death."],"pregnancy":["Pregnancy Category C: Animal reproduction studies have not been conducted with this product. It is not known whether these drugs can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. This product is not recommended for use during pregnancy. Teratogenic Effects Nonteratogenic Effects"],"set_id":"b5a4d051-7a41-45b3-b518-1c833044abb7","spl_product_data_elements":["RESPA PSEUDOEPHEDRINE, CHLORPHENIRAMINE, HYSCYAMINE, ATROPINE, and SCOPOLAMINE CHLORPHENIRAMINE MALEATE CHLORPHENIRAMINE PSEUDOEPHEDRINE HYDROCHLORIDE PSEUDOEPHEDRINE BELLADONNA LEAF BELLADONNA LEAF POVIDONE HYOSCYAMINE SULFATE ATROPINE SULFATE SCOPOLAMINE HYDROCHLORIDE LACTOSE HYPROMELLOSE 2208 (100000 MPA.S) SILICON DIOXIDE STEARIC ACID MAGNESIUM STEARATE RESPA;177"],"teratogenic_effects":["Teratogenic Effects"],"version":"1","warnings":["WARNINGS These tablets may cause drowsiness or blurred vision, patients should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, and not to perform hazardous work. Patients should be warned of possible additive effects caused by taking antihistamines with alcohol, hypnotics, or tranquilizers. In the presence of a high environmental temperature, heat prostration can occur with belladonna alkaloids (fever and heatstroke due to decreased sweating). Sympathomimetic amines should be used with caution in patients eral vascular disease, increased intraocular pressure, hyperthyroidism, or prostatic hypertrophy. Sympathomimetic amines may produce CNS stimulation and convulsions or cardiovascular collapse with accompanying hypotension. Do not exceed recommended dosage. Hypertensive crisis can occur with concurrent use of pseudoephedrine or phenylephrine and MAOI, and for 14 days after stopping MAOI therapy, indomethacin, or with beta-blockers and methyldopa."]}